Colinz Laboratories Limited (531210) Fair Value & Analysis
Healthcare · IN · Market cap ₹24.6M
Fair value as of: Jul 4, 2026
From 13 valuation models · updated today
Share price +25.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹38.64 – ₹85.92 · fair‑value band ₹9.64 – ₹18.25 · the ₹77.55 price screens above the ₹14.60 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Colinz Laboratories Limited (531210) currently trades at ₹77.55, while our model-based Fair Value estimate is ₹14.60 — implying the stock looks roughly 81.2% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Colinz Laboratories Limited generated revenue of ₹69.9M at a net margin of 1.9%. Revenue declined 30.1% year over year. The stock trades on a trailing P/E of 12.6. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Colinz Laboratories Limited manufactures and markets pharmaceutical formulations in India It provides pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams, etc.; and specialized products for gynecology, cardiology, gastroenterology, etc. The company's allopathy products include oncology products and antiritrovirals; and products for other therapeutic areas, such as antibiotics, anti-pyretics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anti-diarrhoeals, anti-inflammatory, anti-piles, anthelmintics, anti-emetics, anti-spasmodics, infestations, sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormone, sunscreens and vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. It also provides ayurvedic products, including anti-diarrhoeals, anti-pyretics, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Colinz Laboratories Limited reported revenue of ₹65.3M in FY2025 versus ₹61.6M in FY2021, a compound +1.5%/yr. Reported net income was ₹5.0M in FY2025, compounding +24.4%/yr from FY2021.
Is 531210 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Syncom Formulations (India) Limited 524470 | ₹14.23 | ₹10.20 | -28% |
| Makers Laboratories Limited 506919 | ₹151.45 | ₹105.20 | -31% |
| Syschem (India) Limited 531173 | ₹40.64 | ₹6.95 | -83% |
| Unjha Formulations Limited 531762 | ₹18.55 | ₹34.60 | +87% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Colinz Laboratories Limited (531210) undervalued?
What is the fair value of 531210?
What is the quality score of 531210?
What is the revenue of Colinz Laboratories Limited (531210)?
What is the net profit margin of 531210?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.